Sanofi SA

Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan

31 May 2024 06:00:00 By Nasdaq GlobeNewswire

Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

31 May 2024 01:05:00 By Nasdaq GlobeNewswire

Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

31 May 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi completes acquisition of Inhibrx, Inc.

30 May 2024 09:01:34 By Nasdaq GlobeNewswire

Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

27 May 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

21 May 2024 01:30:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - April 2024

20 May 2024 16:54:33 By Nasdaq GlobeNewswire

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

20 May 2024 14:15:00 By Nasdaq GlobeNewswire

Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty

13 May 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

10 May 2024 02:00:00 By Nasdaq GlobeNewswire

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations

02 May 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Annual General Meeting of April 30, 2024

30 Apr 2024 12:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance

25 Apr 2024 01:30:00 By Nasdaq GlobeNewswire

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

23 Apr 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

17 Apr 2024 01:00:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - March 2024

12 Apr 2024 14:05:27 By Nasdaq GlobeNewswire

Sanofi - AGM 30.04.2024 - Availability of Preparatory documents

08 Apr 2024 12:00:00 By Nasdaq GlobeNewswire

Press Release: Availability of the Q1 2024 Memorandum for modelling purposes

22 Mar 2024 02:30:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - February 2024

15 Mar 2024 15:04:03 By Nasdaq GlobeNewswire

Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

11 Mar 2024 02:00:00 By Nasdaq GlobeNewswire